In addition, the research group also designed a BRD4-targeting compound PROTAC 28 (Table 1) in 2015, which demonstrated rapid, efficient, and prolonged BRD4 degradation in all tested Burkitt’s lymphoma (BL) cell lines [59]. The gene discussed is BRD4; the disease is Burkitt lymphoma.